ARIA

Development of Appropriate Use Recommendations for lecanemab 6:04
Development of Appropriate Use Recommendations for lecanemab
Stephen Salloway • 19 Apr 2023
Safety results of the Phase III gantenerumab GRADUATE I and II studies 1:50
Safety results of the Phase III gantenerumab GRADUATE I and II studies
Stephen Salloway • 19 Apr 2023
What causes ARIA in response to Alzheimer’s disease immunotherapy? 3:50
What causes ARIA in response to Alzheimer’s disease immunotherapy?
Mourad Tayebi • 30 Mar 2023
Lecanemab: a review 5:24
Lecanemab: a review
Alvaro Pascual-Leone • 9 Jan 2023
Lecanemab vs aducanumab 1:35
Lecanemab vs aducanumab
Alvaro Pascual-Leone • 9 Jan 2023
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk 5:48
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk
Nicolas Villain • 6 Dec 2022
Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA) 6:38
Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA)
Stephen Salloway • 19 Aug 2022
Development of a new anti-amyloid antibody PMN310 for the treatment of Alzheimer’s disease 2:38
Development of a new anti-amyloid antibody PMN310 for the treatment of Alzheimer’s disease
Johanne Kaplan • 17 Mar 2022
The content of VJDementia is intended for healthcare professionals